Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation. 2009

Sabine Meurer, and Sylke Pioch, and Tatjana Pabst, and Nils Opitz, and Peter M Schmidt, and Tobias Beckhaus, and Kristina Wagner, and Simone Matt, and Kristina Gegenbauer, and Sandra Geschka, and Michael Karas, and Johannes-Peter Stasch, and Harald H H W Schmidt, and Werner Müller-Esterl
Department of Pharmacology & Centre for Vascular Health, University of Frankfurt, Germany.

Nitric oxide (NO) is an essential vasodilator. In vascular diseases, oxidative stress attenuates NO signaling by both chemical scavenging of free NO and oxidation and downregulation of its major intracellular receptor, the alphabeta heterodimeric heme-containing soluble guanylate cyclase (sGC). Oxidation can also induce loss of the heme of sGC, as well as the responsiveness of sGC to NO. sGC activators such as BAY 58-2667 bind to oxidized/heme-free sGC and reactivate the enzyme to exert disease-specific vasodilation. Here, we show that oxidation-induced downregulation of sGC protein extends to isolated blood vessels. Mechanistically, degradation was triggered through sGC ubiquitination and proteasomal degradation. The heme-binding site ligand BAY 58-2667 prevented sGC ubiquitination and stabilized both alpha and beta subunits. Collectively, our data establish oxidation-ubiquitination of sGC as a modulator of NO/cGMP signaling and point to a new mechanism of action for sGC activating vasodilators by stabilizing their receptor, oxidized/heme-free sGC.

UI MeSH Term Description Entries
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D010084 Oxidation-Reduction A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471). Redox,Oxidation Reduction
D001808 Blood Vessels Any of the tubular vessels conveying the blood (arteries, arterioles, capillaries, venules, and veins). Blood Vessel,Vessel, Blood,Vessels, Blood
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006152 Cyclic GMP Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed) Guanosine Cyclic 3',5'-Monophosphate,Guanosine Cyclic 3,5 Monophosphate,Guanosine Cyclic Monophosphate,Guanosine Cyclic-3',5'-Monophosphate,3',5'-Monophosphate, Guanosine Cyclic,Cyclic 3',5'-Monophosphate, Guanosine,Cyclic Monophosphate, Guanosine,Cyclic-3',5'-Monophosphate, Guanosine,GMP, Cyclic,Guanosine Cyclic 3',5' Monophosphate,Monophosphate, Guanosine Cyclic
D006162 Guanylate Cyclase An enzyme that catalyzes the conversion of GTP to 3',5'-cyclic GMP and pyrophosphate. It also acts on ITP and dGTP. (From Enzyme Nomenclature, 1992) EC 4.6.1.2. Guanyl Cyclase,Deoxyguanylate Cyclase,Guanylyl Cyclase,Inosinate Cyclase,Cyclase, Deoxyguanylate,Cyclase, Guanyl,Cyclase, Guanylate,Cyclase, Guanylyl,Cyclase, Inosinate
D006418 Heme The color-furnishing portion of hemoglobin. It is found free in tissues and as the prosthetic group in many hemeproteins. Ferroprotoporphyrin,Protoheme,Haem,Heme b,Protoheme IX
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071756 Soluble Guanylyl Cyclase A mammalian enzyme composed of a heterodimer of alpha and beta subunits. Each subunit consists of four domains; N-terminal HNOX domain, PAS-like domain, a coiled-coil domain, and a C-terminal catalytic domain. All four domains are homologous proteins with a similar conformation of functional domains. Soluble guanylate cyclase catalyzes the formation of cyclic GMP from GTP, and is a key enzyme of the nitric oxide signaling pathway involved in the regulation of a variety of biological and physiological processes in mammals. Nitric Oxide Receptor,Nitric Oxide Receptors,Nitric Oxide-Sensitive Guanylyl Cyclase,Receptor, Nitric Oxide,Soluble Guanylate Cyclase,Soluble Guanylyl Cyclase, alpha Subunit,Soluble Guanylyl Cyclase, beta Subunit,Cyclase, Soluble Guanylate,Cyclase, Soluble Guanylyl,Guanylate Cyclase, Soluble,Guanylyl Cyclase, Soluble,Nitric Oxide Sensitive Guanylyl Cyclase,Oxide Receptor, Nitric,Oxide Receptors, Nitric
D014665 Vasodilator Agents Drugs used to cause dilation of the blood vessels. Vasoactive Antagonists,Vasodilator,Vasodilator Agent,Vasodilator Drug,Vasorelaxant,Vasodilator Drugs,Vasodilators,Vasorelaxants,Agent, Vasodilator,Agents, Vasodilator,Antagonists, Vasoactive,Drug, Vasodilator,Drugs, Vasodilator

Related Publications

Sabine Meurer, and Sylke Pioch, and Tatjana Pabst, and Nils Opitz, and Peter M Schmidt, and Tobias Beckhaus, and Kristina Wagner, and Simone Matt, and Kristina Gegenbauer, and Sandra Geschka, and Michael Karas, and Johannes-Peter Stasch, and Harald H H W Schmidt, and Werner Müller-Esterl
March 2003, Analytical biochemistry,
Sabine Meurer, and Sylke Pioch, and Tatjana Pabst, and Nils Opitz, and Peter M Schmidt, and Tobias Beckhaus, and Kristina Wagner, and Simone Matt, and Kristina Gegenbauer, and Sandra Geschka, and Michael Karas, and Johannes-Peter Stasch, and Harald H H W Schmidt, and Werner Müller-Esterl
January 2007, The Journal of biological chemistry,
Sabine Meurer, and Sylke Pioch, and Tatjana Pabst, and Nils Opitz, and Peter M Schmidt, and Tobias Beckhaus, and Kristina Wagner, and Simone Matt, and Kristina Gegenbauer, and Sandra Geschka, and Michael Karas, and Johannes-Peter Stasch, and Harald H H W Schmidt, and Werner Müller-Esterl
September 2005, Current opinion in investigational drugs (London, England : 2000),
Sabine Meurer, and Sylke Pioch, and Tatjana Pabst, and Nils Opitz, and Peter M Schmidt, and Tobias Beckhaus, and Kristina Wagner, and Simone Matt, and Kristina Gegenbauer, and Sandra Geschka, and Michael Karas, and Johannes-Peter Stasch, and Harald H H W Schmidt, and Werner Müller-Esterl
October 1997, Biochemical and biophysical research communications,
Sabine Meurer, and Sylke Pioch, and Tatjana Pabst, and Nils Opitz, and Peter M Schmidt, and Tobias Beckhaus, and Kristina Wagner, and Simone Matt, and Kristina Gegenbauer, and Sandra Geschka, and Michael Karas, and Johannes-Peter Stasch, and Harald H H W Schmidt, and Werner Müller-Esterl
December 2012, The Journal of biological chemistry,
Sabine Meurer, and Sylke Pioch, and Tatjana Pabst, and Nils Opitz, and Peter M Schmidt, and Tobias Beckhaus, and Kristina Wagner, and Simone Matt, and Kristina Gegenbauer, and Sandra Geschka, and Michael Karas, and Johannes-Peter Stasch, and Harald H H W Schmidt, and Werner Müller-Esterl
February 2020, Drug discovery today,
Sabine Meurer, and Sylke Pioch, and Tatjana Pabst, and Nils Opitz, and Peter M Schmidt, and Tobias Beckhaus, and Kristina Wagner, and Simone Matt, and Kristina Gegenbauer, and Sandra Geschka, and Michael Karas, and Johannes-Peter Stasch, and Harald H H W Schmidt, and Werner Müller-Esterl
May 2007, Hypertension (Dallas, Tex. : 1979),
Sabine Meurer, and Sylke Pioch, and Tatjana Pabst, and Nils Opitz, and Peter M Schmidt, and Tobias Beckhaus, and Kristina Wagner, and Simone Matt, and Kristina Gegenbauer, and Sandra Geschka, and Michael Karas, and Johannes-Peter Stasch, and Harald H H W Schmidt, and Werner Müller-Esterl
April 2005, European journal of pharmacology,
Sabine Meurer, and Sylke Pioch, and Tatjana Pabst, and Nils Opitz, and Peter M Schmidt, and Tobias Beckhaus, and Kristina Wagner, and Simone Matt, and Kristina Gegenbauer, and Sandra Geschka, and Michael Karas, and Johannes-Peter Stasch, and Harald H H W Schmidt, and Werner Müller-Esterl
January 2024, European respiratory review : an official journal of the European Respiratory Society,
Sabine Meurer, and Sylke Pioch, and Tatjana Pabst, and Nils Opitz, and Peter M Schmidt, and Tobias Beckhaus, and Kristina Wagner, and Simone Matt, and Kristina Gegenbauer, and Sandra Geschka, and Michael Karas, and Johannes-Peter Stasch, and Harald H H W Schmidt, and Werner Müller-Esterl
January 2013, Journal of cardiovascular pharmacology and therapeutics,
Copied contents to your clipboard!